The Journal of the Royal Society for the Promotion of Health

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nair, D.R.
Right arrow Articles by Mikhailidis, D.P.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
The Journal of the Royal Society for the Promotion of Health, Vol. 121, No. 2, 98-101 (2001)
DOI: 10.1177/146642400112100210
© 2001 Royal Society for the Promotion of Health

Time to look beyond just lowering the serum concentration of low density lipoprotein - high density lipoprotein levels are also important

D.R. Nair

Department of Molecular Pathology and Clinical Biochemistry, Royal Free and University College Medical School, Royal Free Campus, London NW3 2QG, England

A.S. Wierzbicki

Department of Chemical Pathology, King's College London (Guy's, King's and St. Thomas' Medical School), St. Thomas' Hospital Campus, London SE1 7EH, England

D.P. Mikhailidis

Department of Molecular Pathology and Clinical Biochemistry, Royal Free and University College Medical School, Royal Free Campus, Pond Street, London NW3 2QG, England

There is convincing epidemiological evi dence indicating that the serum levels of high density lipoprotein (HDL) cholesterol are inversely related to the risk of vascular events. Similarly, intervention trials, involving healthy populations and patients with coro nary heart disease (CHD), have shown that raising the serum levels of HDL is associat ed with a significant decrease in the risk of vascular events. It follows that serum HDL levels must be considered when assessing risk and setting therapeutic goals. Some of the currently available national treatment guide lines reflect this view The present review considers the place of serum HDL measure ment in the prevention of vascular events.

Key Words: Cholesterol • coronary heart disease (CHD) • high density lipoprotein (HDL) • low density lipoprotein (LDL)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?